



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Bae Abertawe
Swansea Bay University
Health Board

Cadeirydd/Chair: **Emma Woollett**
Prif Weithredwr/Chief Executive: **Tracy Myhill**

gofalu am ein gilydd, cydweithio, gwella bob amser
caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 2nd July 2020
Ein Cyf / Our Ref: 20-F-010

☎ 01639 648363
✉ FOIA.Requests@wales.nhs.uk

Corporate Services
Headquarters
1 Talbot Gateway
Baglan
Port Talbot, SA12 7BR

Dear

I refer to your Freedom of Information Act Request acknowledged by ourselves on 10th June 2020. Your request sought information relating to growth hormones.

Please note that the information we have provided covers the period 01.04.19 to 31.03.20.

We are unable to provide information per clinical indication, therefore total prescribed/dispensed numbers have been provided unless otherwise specified. With regards to primary care data, patient-level data is not held by the Health Board, but is held within the individual GP practices, however we do hold information on the total number of items prescribed within primary care (whereby one item equates to one prescription).

1. In your Health Board how many patients have been treated with the following Somatostatin Analogues in the latest 12-month period for which data are available?

Octreotide

Primary Care - 52 items prescribed for all clinical indications

Secondary Care - 34 patients treated for all clinical indications. (Patient numbers likely to be higher as medicine is issued as ward stock, and direct-patient numbers is not available within the current system).

Lanreotide

Primary Care - 17 items prescribed for all clinical indications

Secondary Care – 17 patients treated for all clinical indications



Pencadlys BIP Bae Abertawe, Un Porthfa Talbot, Port Talbot, SA12 7BR / Swansea Bay UHB Headquarters, One Talbot Gateway, Port Talbot, SA12 7BR

Bwrdd Iechyd Prifysgol Bae Abertawe yw enw gweithredu Bwrdd Iechyd Lleol Prifysgol Bae Abertawe
Swansea Bay University Health Board is the operational name of Swansea Bay University Local Health Board

Pasireotide – 0

2. In the latest 12-month period how many Acromegaly patients have been treated with the following drugs?

Sandostatin LAR

Primary Care - 23 items prescribed for all clinical indications

Secondary Care – <5 patients treated for all clinical indications

Octreotide Long-Acting (Generic)

Secondary Care – 9 patients treated for all clinical indications

Somatuline Autogel

Primary Care - 17 items prescribed for all clinical indications

Secondary Care – 41 patients treated for all clinical indications

Pasireotide - 0

Pegvisomant

Secondary Care – <5 patients treated for all clinical indications

3. How many patients have received a Somatropin treatment for growth hormone deficiency in the latest 12-month period?

Genotropin

Primary Care - 190 items prescribed for all clinical indications

Secondary Care – <5 patients treated for all clinical indications

Humatrope

Primary Care - 16 items prescribed for all clinical indications

Norditropin

Primary Care - 167 items prescribed for all clinical indications

Secondary Care – 11 patients treated for all clinical indications

Nutropin

Primary Care - 12 items prescribed for all clinical indications

Omnitrope

Primary Care - 129 items prescribed for all clinical indications

Secondary Care – <5 patients treated for all clinical indications

Saizen

Primary Care - 34 items prescribed for all clinical indications

Zomacton

Primary Care - 12 items prescribed for all clinical indications

Secondary Care – <5 patients treated for all clinical indications

4. If it is possible, can you provide the number of patients under the age 16 that were treated with each of the following drugs in the latest 12-month period?



Please note that we are only able to filter ages of patients for secondary care, as we do not hold patient-level data for primary care.

Genotropin <5 patients

Humatrope 0 patients

Norditropin <5 patients

Nutropin 0 patients

Omnitrope 0 patients

Saizen 0 patients

Zomacton <5 patients

Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

I hope this information is helpful. If you require anything further please contact us at FOIA.Requests@wales.nhs.uk.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via FOIA.Requests@wales.nhs.uk.

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger
Director of Corporate Governance

